

A - ORIGINAL ARTICLES IN PEER REVIEWED JOURNALS

(Alphabetisch nach Erstautor sortiert)

AGAZZI P, BIEN CG, STAEDLER C, BIGLIO V, **GOBBI C**

Over 10-year follow-up of limbic encephalitis associated with anti-LGI1 antibodies.

J Neurol 2014 Dec 12. [Epub ahead of print] IF: 3.841

ALTINBAS A, HENDRIKSE J, ALGRA A, VAN ZANDVOORT MJ, BROWN MM, **BONATI LH**, DE BORST GJ, KAPPELLE LJ, VAN DER WORP HB.

Ipsilateral foetal-type posterior cerebral artery is associated with cognitive decline after carotid revascularisation.

BMC Neurol. 2014; 14:84. IF: 2.468

ALTINBAS A, ALGRA A, **BONATI LH**, BROWN MM, KAPPELLE LJ, DE BORST GJ, HENDRIKSE J, VAN DT, I, VAN DER WORP HB, ICSS Investigators.

Periprocedural Hemodynamic Depression Is Associated With a Higher Number of New Ischemic Brain Lesions After Stenting in the International Carotid Stenting Study-MRI Substudy.

Stroke. 2014; 45: 146-151. IF: 6.018

AMANN M, ANDĚLOVÁ M, PFISTER A, M, TRAUD S, REINHARDT J, MAGON S, BENDFELDT K, KAPPOS L, RADUE EW, STIPPICH C, SPRENGER T

Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST).

Neuroimage Clin. 2014;7:43-52. IF: -

AMANN M, SPRENGER T, NAEGELIN Y, REINHARDT J, KUSTER P, HIRSCH JG, KAPPOS L, RADUE EW, STIPPICH C, BIERI O.

Comparison between balanced steady-state free precession and standard spoiled gradient echo magnetization transfer ratio imaging in multiple sclerosis: methodical and clinical considerations.

Neuroimage. 2014;108C:87-94. IF: 6.132

AMOR S, VAN DER STAR BJ, BOSCA I, RAFFEL J, GNANAPAVAN S, WATCHORN J, **KUHLE J, GIOVANNONI G, BAKER D, MALASPINA A, PUENTES F.**

Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.

Mult Scler 2014; 20:1355-1362 IF: 4.863

ARNOLD DL, GOLD R, **KAPPOS L**, BAR-OR A, GIOVANNONI G, SELMAJ K, YANG M; ZHANG R, STEPHAN M, SHEIKH S, DAWSON K

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

J Neurol 2014;261:1794-1802 IF: 3.841

ARNOLD DL, GOLD R, **KAPPOS L**, BAR-OR A, GIOVANNONI G, SELMAJ K, YANG M, ZHANG R, STEPHAN M, SHEIKH SI, DAWSON K

Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study.

J Neurol. 2014;261(12):2429-37. IF: 3.841

ASCHERIO A, MUNGER KL, WHITE R, KÖCHERT K, SIMON KC, POLMAN CH, FREEDMAN MS, HARTUNG HP, MILLER DH, MONTALBÁN X, EDAN G, BARKHOF F, PLEIMES D, RADUE EW, SANDBRINK R, **KAPPOS L**, POHL C

Vitamin D as an early predictor of multiple sclerosis activity and progression

JAMA Neurol 2014; 71(3):306-14. IF: 7.01

BENZ N, **HATZ F, BOUSLEIMAN H**, EHRENSPERGER MM, **GSCHWANDTNER U, HARDMEIER M, RÜEGG S**, SCHINDLER C, **ZIMMERMANN R**, MONSCH AU, **FUHR P.**

Slowing of EEG background activity in Parkinson's and Alzheimer's disease with early cognitive dysfunction.

Front Aging Neurosci. 2014;6:314. IF: 2.843

BÉJOT Y, ABOA-BOULÉ C, DEBETTE S, PEZZINI A, TATLISUMAK T, **ENGELTER S**, GROND-GINSBACH C, TOUZÉ E, SESSA M, METSO T, METSO A, KLOSS M, CASO V, DALLONGEVILLE J, **LYRER P**, LEYS D, GIROUD M, PANDOLFO M, ABOUD S for the CADISP Group.
Characteristics and outcomes of patients with multiple cervical artery dissection.
Stroke 2014; 45(1):37-41. IF: 6.018

BISCHOF A, SPRENGER T.

Interferon beta-associated recurrence of painful trigeminal neuropathy attributed to a multiple sclerosis plaque.
J Headache Pain. 2014; 15:21. IF: 3.281

BONATI LH, DOBSON J, FEATHERSTONE RL, EDERLE J, VAN DER WORP HB, DE BORST GJ, MALI WP, BEARD JD, CLEVELAND T, **ENGELTER S**, **LYRER PA**, FORD GA, DORMAN PJ, BROWN MM, for the International Carotid Stenting Study Investigators.

Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial.
Lancet. 2014 Oct 14 [Epub ahead of print] IF: 39.207

BONATI LH, EDERLE J, DOBSON J, **ENGELTER S**, FEATHERSTONE RL, GAINES PA, BEARD JD, VENABLES GS, MARKUS HS, CLIFTON A, SANDERCOCK P, BROWN MM, on behalf of the CAVATAS Investigators.

Length of carotid stenosis predicts peri-procedural stroke or death and restenosis in patients randomized to endovascular treatment or endarterectomy.
Int J Stroke. 2014; 9(3): 297-305. IF: 4.029

BONATI U, BECHTEL N, HEINIMANN K, RUTZ E, SCHNEIDER J, FRANK S, WEBER P, **FISCHER D**.
Congenital muscular dystrophy with dropped head phenotype and cognitive impairment due to a novel mutation in the LMNA gene.
Neuromuscul Disord. 2014; 24(6): 529-32. IF: 3.134

BOUSLEIMAN H, ZIMMERMANN R, AHMED S, HARDMEIER M, HATZ F, SCHINDLER C, ROTH V, GSCHWANDTNER G, FUHR P.

Power spectra for screening parkinsonian patients for mild cognitive impairment.
Ann Clin Transl Neurol. 2014;1(11):884-90. IF: -

BRIDEL C, HORVATH J, KURIAN M, TRUFFERT A, **STECK A**, LALIVE PH.
Multifocal motor neuropathy with high titers of anti-MAG antibodies.
J Peripher Nerv Syst. 2014;19(2):180-2. IF: 2.504

BRODERICK JP, PALESCH YY, DEMCHUK AM, YEATTS SD, KHATRI P, HILL MD, JAUCH EC, JOVIN TG, YAN B, VON KUMMER R, MOLINA CA, GOYAL M, MAZIGHI M, SCHONEWILLE WJ, **ENGELTER S**, ANDERSON C, SPILKER J, CARROZZELLA J, JANIS LS, FOSTER LD, TOMSICK TA; Interventional Management of Stroke III Investigators.
Evolution of Practice During the Interventional Management of Stroke III Trial and Implications for Ongoing Trials.
Stroke. 2014; 45(12):3606-11. IF: 6.018

BUROW A, LYRER PA, NEDERKOORN PJ, BROWN MM, SZTAJZEL R, ENGELTER S, BONATI LH

Echographic risk index and cerebral ischemic brain lesions in patients randomized to stenting versus endarterectomy for symptomatic carotid artery stenosis.
Ultraschall Med. 2014; 35: 267-272. IF: 4.645

BUTZKUEVEN H, **KAPPOS L**, PELLEGRINI F, TROJANO M, WIENDL H, PATEL RN, ZHANG A, HOTERMANS C, BELACHEW S; Tysabri Observational Program (TOP) investigators
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
J Neurol Neurosurg Psychiatry 2014;85(11):1190-7. IF: 5.580

CALABRESI PA, RADUE EW, GOODIN D, JEFFERY D, RAMMOHAN KW, REDER AT, VOLLMER T, AGIUS MA, **KAPPOS L**, STITES T, LI B, CAPIELLO L, VON ROSENSTIEL P, LUBLIN FD
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Neurol. 2014 Jun;13(6):545-56. IF: 21.823

CALVET D, MAS JL, ALGRA A, BECQUEMIN JP, **BONATI LH**, DOBSON J, FRAEDRICH G, JANSEN O, MALI WP, RINGLEB PA, CHATELLIER G, BROWN MM, Carotid Stenting Trialists Collaboration.
Carotid stenting: is there an operator effect? A pooled analysis from the carotid stenting trialists' collaboration.
Stroke. 2014; 45: 527-532. IF: 6.018

CAPORRO M, DISANTO G, **GOBBI C**, ZECCA C.
Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.
Patient Prefer Adherence. 2014;8:1123-34. IF: 1.491

CLAASSEN J, ALBERS D, SCHMIDT JM, **DE MARCHIS GM**, PUGIN D, FALO CM, MAYER SA, CREMERS S, AGARWAL S, ELKIND MS, CONNOLLY ES, DUKIC V, HRIPCSAK G, BADJATIA N.
Nonconvulsive seizures in subarachnoid hemorrhage link inflammation and outcome.
Ann Neurol 2014; 75:771-81. IF: 11.910

COMI G, GOLD R, DAHLKE F, SINHA A, VON ROSENSTIEL P, TOMIC D, **KAPPOS L**
Relapses in patients treated with fingolimod after previous exposure to natalizumab.
Mult Scler J 2014 Sep 25. [Epub ahead of print] IF: 4.863

CONFAVREUX C, O'CONNOR P, COMI G, FREEDMAN MS, MILLER AE, OLSSON TP, WOLINSKY JS, BAGULHO T, DELHAY JL, DUKOVIC D, TRUFFINET P, **KAPPOS L**; TOWER TRIAL GROUP
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Neurol 2014; 13(3):247-56. IF: 21.823

DEBETTE S, GOEGGEL SIMONETTI B, SCHILLING S, MARTIN JJ, KLOSS M, SARIKAYA H, HAUSSER I, **ENGELTER S**, METSO TM, PEZZINI A, THIJIS V, TOUZÉ E, PAOLUCCI S, COSTA P, SESSA M, SAMSON Y, BÉJOT Y, ALTINTAS A, METSO AJ, HERVÉ D, LICHY C, JUNG S, FISCHER U, LAMY C, GRAU A, CHABRIAT H, CASO V, **LYRER PA**, STAPF C, TATLISUMAK T, BRANDT T, TOURNIER-LASSERVE E, GERMAIN DP, FRANK M, BAUMGARTNER RW, GROND-GINSBACH C, BOUSSER MG, LEYS D, DALLONGEVILLE J, BERSANO A, ARNOLD M; CADISP-plus consortium.
Familial occurrence and heritable connective tissue disorders in cervical artery dissection.
Neurology. 2014 Nov 25; 83(22): 2023-31. IF: 8.303

DE MARCHIS GM, WECK A, AUDEBERT H, BENIK S, FOERCH C, BUHL D, SCHUETZ P, JUNG S, SEILER M, MORGENTHALER N, MATTLE H, MUELLER B, CHRIST-CRAIN M, ARNOLD M, KATAN M.
Copeptin For The Prediction Of Recurrent Cerebrovascular Events After TIA - Results From The CoRisk Study.
Stroke 2014; 45: 2918-23 IF: 6.018

DE MARCHIS GM, FILIPPI CG, GUO X, PUGIN D, GAFFNEY CD, DANGAYACH NS, SUWATCHARANGKON S, FALO MC, SCHMIDT JM, AGARWAL S, CONNOLLY ES JR, CLAASSEN J, ZHAO B, MAYER SA.
Brain Injury Visible On Early MRI After Subarachnoid Hemorrhage Might Predict Neurological Impairment And Functional Outcome.
Neurocrit Care 2014;Jul 11. [Epub ahead of print]. IF: 2.604

DE MARCHIS GM, LANTIGUA H, SCHMIDT JM, LORD A, VELANDER A, FERNANDEZ A, FALO CM, AGARWAL S, CONNOLLY ES JR, CLAASSEN J, MAYER SA.
Impact Of Premorbid Hypertension On Hemorrhage Severity And Aneurysm Rebleeding Risk After Subarachnoid Hemorrhage.
J Neurol Neurosurg Psychiatry 2014; 85:56-9. IF: 5.580

DE STEFANO N, COMI G, **KAPPOS L**, FREEDMAN MS, POLMAN CH, UITDEHAAG BMJ, HENNESSY B, CASSET-SEMANAZ F, LEHR L, STUBINSKI B, JACK DL, BARKHOF F
Efficacy of subcutaneous interferon β -1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
J Neurol Neurosurg Psychiatry 2014;85(6):647-53 IF: 5.580

DEMCHUK AM, GOYAL M, YEATTS SD, CARROZZELLA J, FOSTER LD, QAZI E, HILL MD, JOVIN TG, RIBO M, YAN B, ZAIDAT OO, FREI D, VON KUMMER R, COCKROFT KM, KHATRI P, LIEBESKIND DS, TOMSICK TA, PALESCH YY, BRODERICK JP; IMS III Investigators*.(***ENGELTER S** Co-Investigator)
Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial.
Radiology. 2014; 273(1):202-10. IF: 6.214

DERFUSS T, CURTIN F, **GUEBELIN C**, BRIDEL C, **RASENACK M**, MATTHEY A, PASQUIER RD, SCHLUEP M, DESMEULES J, LANG AB, PERRON H, FAUCARD R, PORCHET H, HARTUNG HP, **KAPPOS L**, LALIVE PH
A phase IIa randomised clinical study of GNBAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Mult Scler J 2014 Nov 12. [Epub ahead of print] IF: 4.863

DIMOPOULOU C, ATHANASOULIA AP, HANISCH E, HELD S, **SPRENGER T**, TOELLE TR, RÖMMLER-ZEHRER J, SCHOPOHL J, STALLA GK, **SIEVERS C**.
The clinical characteristics of pain in patients with pituitary adenomas.
Eur J Endocrinol 2014;171:581-591. IF: 3.686

DISANTO G, KJETIL SANDVE G, RICIGLIANO VA, PAKPOOR J, BERLANGA-TAYLOR AJ, HANDEL AE, **KUHLE J**, HOLDEN L, WATSON CT, GIOVANNONI G, HANDUNNETTHI L, RAMAGOPALAN SV.
DNase hypersensitive sites and association with multiple sclerosis.
Hum Mol Genet 2014; 23:942-948 IF: 6.677

DISANTO G, DOBSON R, PAKPOOR J, ELANGO VAN RI, ADIUTORI R, **KUHLE J**, GIOVANNONI G.
The refinement of genetic predictors of multiple sclerosis.
PLoS One 2014; 9:e96578 IF: 3.53

DOERNER M, BECKMANN K, KNAPPERTZ V, **KAPPOS L**, HARTUNG HP, FILIPPI M, O'CONNOR PW, ARNASON B, COOK S, JEFFERY D, COMI G, LIMMROTH V
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study
Eur Neurol 2014; 71(3-4):173-179. IF: 1.362

DREXLER I*, **TRAENKA C***, VON HESSLING A, **GENSICKE H** (*contributed equally)
Internal carotid artery dissection and asymmetrical facial flushing: the Harlequin sign.
Stroke 2014;45(5):e78-80. IF: 6.158

EDAN G*, **KAPPOS L***, MONTALBÁN X, POLMAN CH, FREEDMAN MS, HARTUNG HP, MILLER D, BARKHOF F, HERRMANN J, LANIUS V, STEMPER B, POHL C, SANDBRINK R, PLEIMES D; BENEFIT STUDY GROUP (* equal contribution)
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
J Neurol Neurosurg Psychiatry 2014;85(11):1183-9 IF: 5.580

FILIPPI M, ROCCA MA, PAGANI E, DE STEFANO N, JEFFERY D, **KAPPOS L**, MONTALBAN X, BOYKO AN, COMI G; on behalf of the ALLEGRO Study Group
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
J Neurol Neurosurg Psychiatry 2014; 85(8):851–858 IF: 5.58

FISCHER D, SCHABHÜTTL M, WIELAND T, WINDHAGER R, STROM TM, AUER-GRUMBACH M
A novel missense mutation confirms ATL3 as a gene for hereditary sensory neuropathy type 1.
Brain 2014;137(Pt 7):e286 IF: 10.226

FLACHENECKER P, BUCKOW K, PUGLIATTI M, KES VB, BATTAGLIA MA, BOYKO A, CONFAVREUX C, ELLENBERGER D, ESKIC D, FORD D, FRIEDE T, FUGE J, GLASER A, HILLERT J, HOLLOWAY E, IOANNIDOU E, **KAPPOS L**, KASILINGAM E, KOCH-HENRIKSEN N, **KUHLE J**, LEPORE V, MIDDLETON R, MYHR KM, OROLOGAS A, OTERO-ROMERO S, PITSCHNAU-MICHEL D, RIENHOFF O, SASTRE-GARRIGA J, SCHYNS-LIHARSKA T, SUTOVIC D, THALHEIM C, TROJANO M, VLASOV YV, **YALDIZLI O**
Multiple sclerosis registries in Europe - results of a systematic survey.
Mult Scler 2014;20(11):1523-32. IF: 4.863

FOX RJ, CAMPBELL CREE BA, DE SÈZE J, GOLD R, HARTUNG HP, JEFFERY D, **KAPPOS L**, KAUFMAN M, MONTALBÁN X, WEINSTOCK-GUTTMAN B, ANDERSON B, NATARAJAN A, TICHO B, DUDA P.
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.
Neurology 2014;82(17):1491-8. IF: 8.303

FRANCIS G, **KAPPOS L**, O'CONNOR P, COLLINS W, TANG D, MERCIER F, COHEN JA
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
Mult Scler J 2014; 20(4):471-80. IF: 4.863

FREEDMAN MS, DE STEFANO N, BARKHOF F, POLMAN CH, COMI G, UITDEHAAG BM, CASSET-SEMANAZ F, HENNESSY B, LEHR L, STUBINSKI B, JACK DL, **KAPPOS L**
Patient subgroup analyses of the treatment effect of subcutaneous interferon β -1a on development of multiple sclerosis in the randomized controlled REFLEX study
J Neurol 2014; 261(3):490-9. IF: 3.841

FRITSCHI SK, LANGER F, KAESER SA, MAIA LF, PORTELIUS E, PINOTSI D, KAMINSKI CF, **WINKLER DT**, MAETZLER W, KEYVANI K, SPITZER P, WILTFANG J, KAMINSKI SCHIERLE GS, ZETTERBERG H, STAUFENBIEL M, JUCKER M.
Highly potent soluble amyloid- β seeds in human Alzheimer brain but not cerebrospinal fluid.
Brain. 2014;137(Pt 11):2909-15. IF: 10.226

GIBBS E, KARIM ME, OGER J; the Steering Committee of the BENEFIT study* (* **KAPPOS L** member of the Steering Committee)
Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: A comparison of interferon beta-1b-treated patients with transient versus sustained NABs.
Clin Immunol. 2014 Dec 24; [Epub ahead of print] IF: 2.654

GOBBI C, ROCCA MA, PAGANI E, RICCITELLI GC, PRAVATÀ E, RADAELLI M, MARTINELLI-BONESCHI F, FALINI A, COPETTI M, COMI G, FILIPPI M
Forceps minor damage and co-occurrence of depression and fatigue in multiple sclerosis.
Mult Scler J 2014;20(12):1633-40. IF: 4.863

GOBBI C, ROCCA MA, RICCITELLI G, PAGANI E, MESSINA R, PREZIOSA P, COLOMBO B, RODEGHER M, FALINI A, COMI G, FILIPPI M
Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis.
Mult Scler J 2014;20(2):192-201. IF: 4.863

GOLD R, COMI G, PALACE J, SIEVER A, GOTTSCHALK R, BIJARNIA M, VON ROSENSTIEL P, TOMIC D, **KAPPOS L**; FIRST STUDY INVESTIGATORS
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
J Neurol 2014; 261(2):267-76. Erratum in: J Neurol 2014; 261(4):850. IF: 3.841

GRIMM A, **DECARD BF**, **BISCHOF A**, AXER H
Ultrasound of the peripheral nerves in systemic vasculitic neuropathies.
J Neurol Sci. 2014; 347(1-2):44-9. IF: 2.262

GRIMM A, **DÉCARD BF**, AXER H
Ultrasonography of the peripheral nerve system in the early stage of Guillain-Barré syndrome.
Journal of the peripheral nervous system
J Peripher Nerv Syst. 2014; 19(3): 234-41. IF: 2.50

GRIMM A, HEILING B, SCHUMACHER U, WITTE OW, AXER H
Ultrasound differentiation of axonal and demyelinating neuropathies.
Muscle Nerve. 2014;50(6):976-83. IF: 2.311

GRIMM A, PRELL T, DÉCARD BF, SCHUMACHER U, AXER H, GROSSKREUTZ J
Muscle ultrasonography as an additional diagnostic tool for the diagnosis of amyotrophic lateral sclerosis
Clin. Neurophysiology 2014 Aug 21. [Epub ahead of print] IF: 3.14

GRIMM A, THOMASER AL, PETERS N, FUHR P.
Vagal hypertrophy in immune-mediated neuropathy visualised with high-resolution ultrasound (HR-US).
J Neurol Neurosurg Psychiatry. 2014 Sep 10. [Epub ahead of print] IF: 5.580

HAFNER P, BONATI U, FISCHMANN A, SCHNEIDER J, FRANK S, MORRIS-ROSENDAHL DJ, DUMEA A, HEINIMANN K, FISCHER D
Skeletal muscle MRI in congenital muscular dystrophy patients with a novel POMT1 and POMT2 mutation.
Neuromuscul Disord. 2014; 24(4):321-4. IF: 3.134

HARDMEIER M, HATZ F, NAEGELIN Y, HIGHT D, SCHINDLER C, KAPPOS L, SEECK M, MICHEL CM, FUHR P.
Improved characterization of visual evoked potentials in multiple sclerosis by topographic analysis.
Brain Topogr. 2014; 27(2):318-27. IF: 2.519

HARDMEIER M, HATZ F, BOUSLEIMAN H, SCHINDLER C, STAM CJ, FUHR P.
Reproducibility of functional connectivity and graph measures based on the phase lag index (PLI) and weighted phase lag index (wPLI) derived from high resolution EEG.
PLoS One. 2014;9(10):e108648. IF: 3.534

HOFSTETTER L, NAEGELIN Y, FILLI L, KUSTER P, TRAUD S, SMIESKOVA R, MUELLER-LENKE N, KAPPOS L, GASS A, SPRENGER T, PENNER IK, NICHOLS TE, VRENKEN H, BARKHOF F, POLMAN C, RADUE EW, BORGWARDT SJ, BENDFELDT K
Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis
Mult Scler J 2014; 20(2):202-13. IF: 4.863

IZQUIERDO G, O'CONNOR P, MONTALBAN X, VON ROSENSTIEL P, CREMER M, DE VERA A, SFIKAS N, FRANCIS G, RADUE E, KAPPOS L
Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis
Mult Scler J 2014; 20(7): 877-881. IF: 4.863

KAMM CP, EL-KOUSSY M, HUMPERT S, FINDLING O, BURREN Y, SCHWEGLER G, DONATI F, MÜLLER M, MÜLLER F, SLOTBOOM J, KAPPOS L, NAEGELIN Y, MATTLE HP; SWABIMS STUDY GROUP
Atorvastatin added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial
PLoS One 2014; 9(1):e86663. IF: 3.534

KAPPOS L, GOLD R, ARNOLD DL, BAR-OR A, GIOVANNONI G, SELMAJ K, SARDA SP, AGARWAL S, ZHANG A, SHEIKH SI, SEIDMAN E, DAWSON KT
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study
Mult Scler J 2014; 20(2):243-52. IF: 4.863

KAPPOS L, COHEN J, COLLINS W, DE VERA A, ZHANG-AUBERSON L, RITTER S, VON ROSENSTIEL P, FRANCIS G
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
Mult Scler Relat Disord 2014; (3): 494-504. IF: 0.328

KAPPOS L, HARTUNG HP, FREEDMAN MS, BOYKO A, RADUE EW, MIKOL DD, FREUDENSPRUNG U, LAMARINE M, HYVERT Y, PLITZ T, VAN BEEK J; ATAMS STUDY GROUP
Atacicept in Multiple Sclerosis (ATAMS): a randomized, placebo-controlled, double-blind, phase 2 trial
Lancet Neurol 2014;13(4):353-63. IF: 21.823

KARLSSON G, FRANCIS G, KOREN G, HEINING P, ZHANG X, COHEN JA, **KAPPOS L**, COLLINS W
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis
Neurology 2014; 82(8):674-80. IF: 8.303

KAUFMAN M, CREE BA, DE SÈZE J, FOX RJ, GOLD R, HARTUNG HP, JEFFERY D, **KAPPOS L**,
MONTALBÁN X, WEINSTOCK-GUTTMAN B, TICHÓ B, DUDA P, PACE A, CAMPAGNOLO D
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
J Neurol 2014 Nov 9. [Epub ahead of print] IF: 3.841

KEARNEY H, ROCCA M, VALSASINA P, BALK L, SASTRE-GARRIGA J, REINHARDT J, RUGGIERI S,
ROVIRA A, STIPPICH C, **KAPPOS L**, **SPRENGER T**, TORTORELLA P, ROVARIS M, GASPERINI C,
MONTALBAN X, GEURTS J, POLMAN C, BARKHOF F, FILIPPI M, ALTMANN D, CICCARELLI O, MILLER
D, CHARD D
Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long
disease duration
Mult Scler J 2014; 20(1):72-80. IF: 4.863

KHATRI BO, PELLETIER J, **KAPPOS L**, HARTUNG HP, COMI G, BARKHOF F, VON ROSENSTIEL P,
MENG X, GRINSPAN A, HASHMONAY R, COHEN JA ON BEHALF OF THE TRANSFORMS STUDY
GROUP
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs.
interferon β -1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. fingolimod
Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)
Mult Scler Relat Disord 2014; 3 (3): 355-63. IF: 0.328

KILLEEN T, **CZAPLINSKI A**, CESNULIS E
Extradural spinal cavernous malformation: a rare but important mimic.
Br J Neurosurg 2014;28(3):340-6. IF: 0.947

KITA M, FOX RJ, GOLD R, GIOVANNONI G, PHILLIPS JT, SARDA SP, KONG J, VIGLIETTA V, SHEIKH
SI, OKWUOKENYE M, **KAPPOS L**
Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with
relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
Clin Ther. 2014;36(12):1958-71. IF: 2.586

KLOSS M, GROND-GINSBACH C, PEZZINI A, METSO TM, METSO AJ, DEBETTE S, LEYS D,
DALLONGEVILLE J, CASO V, THIJS V, BERSANO A, TOUZE E, **BONATI LH**, TATLISUMAK T, ARNOLD
ML, **LYRER PA**, **ENGELTER S**, Cervical Artery Dissection and Ischemic Stroke Patients (CADISP) Study
Group.
Stroke in first-degree relatives of patients with cervical artery dissection.
Eur J Neurol. 2014; 21(8): 1102-7. IF: 3.852

KREMENCHUTZKY M, O'CONNOR P, HOHLFELD R, ZHANG-AUBERSON L, VON ROSENSTIEL P,
MENG X, GRINSPAN A, HASHMONAY R, **KAPPOS L**
Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod:
Subgroup analyses of the fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis
(FREEDOMS) study
Mult Scler Relat Disord 2014; 3 (3): 341-49. IF: 0.328

KUHLE J, GAIOTTINO J, LEPPERT D, PETZOLD A, BESTWICK JP, MALASPINA A, LU CH, DOBSON R,
DISANTO G, NORGREN N, NISSIM A, **KAPPOS L**, HURLBERT J, YONG VW, GIOVANNONI G, CASHA S.
Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome.
J Neurol Neurosurg Psychiatry 2014 June 16 [Epub ahead of print] IF: 5.580

KUHLE J, DISANTO G, DOBSON R, ADIUTORI R, BIANCHI L, TOPPING J, BESTWICK JP, MEIER UC, COSTA GD, RUNIA T, EVDOSHENKO E, NATALIA L, THOUVENOT E, IAFFALDANO P, DIRENZO V, MOHSEN K, PIEHL F, COMABELLA M, SOMBEKKE M, KILLESTEIN J, HARALD H, RAUCH S, D'ALFONSO S, ALVAREZ-CERMEÑO JC, KLEINOVÁ P, HORÁKOVÁ D, ROESLER R, LAUDA F, LLUFRIU S, TIMUCIN A, UYGUNOGLU U, ALTINTAS A, SAIP S, MENGE T, RAJDA C, BERGAMASCHI R, MOLL N, KHALIL M, MARIGNIER R, DUJMOVIC I, LARSSON H, MALMESTROM C, SCARPINI E, FENOGLIO C, WERGELAND S, LARONI A, ANNIBALI V, ROMANO S, MARTÍNEZ AD, CARRA A, SALVETTI M, UCCELLI A, TORKILDSEN O, MYHR K, GALIMBERTI D, REJDAK K, LYCKE J, FREDERIKSEN JL, DRULOVIC J, CONFAYREUX C, BRASSAT D, ENZINGER C, FUCHS S, BOSCA I, PELLETIER J, PICARD C, COLOMBO E, FRANCIOTTA D, **DERFUSS T**, **LINDBERG RL**, **YALDIZLI O**, VÉCSEI L, KIESEIER BC, HARTUNG HP, VILLOSLADA P, SIVA A, SAIZ A, TUMANI H, HAVRDOVÁ E, VILLAR LM, LEONE M, BARIZZONE N, DEISENHAMMER F, TEUNISSEN C, MONTALBAN X, TINTORÉ M, OLSSON T, TROJANO M, LEHMANN S, CASTELNOVO G, LAPIN S, HINTZEN R, **KAPPOS L**, FURLAN R, MARTINELLI V, COMI GC, RAMAGOPALAN S, GIOVANNONI G.

Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study
Mult Scler J 2014;20:1523-32. IF 4.863

LU CH, PETZOLD A, TOPPING J, ALLEN K, MACDONALD-WALLIS C, CLARKE J, PEARCE N, **KUHLE J**, GIOVANNONI G, FRATTA P, SIDLE K, FISH M, ORRELL R, HOWARD R, GREENSMITH L, MALASPINA A.

Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study.

J Neurol Neurosurg Psychiatry 2014 July 9 [Epub ahead of print] IF: 5.580

LUKAS C, KNOL DL, SOMBEKKE MH, BELLENBERG B, HAHN HK, POPESCU V, **WEIER K**, RADUE EW, GASS A, **KAPPOS L**, **NAEGELIN Y**, UITDEHAAG BM, GEURTS JJ, BARKHOF F, VRENKEN H

Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis.

J Neurol Neurosurg Psychiatry 2014 Jun 27. [Epub ahead of print] IF: 5.580

LYRER PA, BRANDT T, METSO TM, METSO AJ, KLOSS M, DEBETTE S, LEYS D, CASO V, PEZZINI A, **BONATI LH**, THIJS V, BERSANO A, TOUZE E, **GENSICKE H**, MARTIN JJ, LICHY C, TATLISUMAK T, **ENGELTER S**, GROND-GINSBACH C, for the Cervical Artery Dissection and Ischemic Stroke Patients (CADISP) Study Group.

Clinical importance of Horner syndrome in internal carotid and vertebral artery dissection.

Neurology. 2014; 82(18): 1653-1659. IF: 8.303

MAGON S, CHAKRAVARTY MM, **AMANN M**, **WEIER K**, **NAEGELIN Y**, **ANDELOVA M**, RADUE EW, STIPPICH C, LERCH JP, **KAPPOS L**, **SPRENGER T**.

Label-fusion-segmentation and deformation-based shape analysis of deep gray matter in multiple sclerosis: the impact of thalamic subnuclei on disability.

Hum Brain Mapp 2014;35:4193-203. IF: 6.924

MAGON S, **GAETANO L**, CHAKRAVARTY MM, LERCH JP, **NAEGELIN Y**, STIPPICH C, **KAPPOS L**, RADUE EW, **SPRENGER T**.

White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study.

BMC Neurosci 2014;15:106. IF: 2.845

MANIYAR FH*, **SPRENGER T***, MONTEITH T, SCHANKIN C, GOADSBY PJ. (*equally contributing first authors)

Brain activations in the premonitory phase of nitroglycerin triggered migraine attacks.

Brain 2014; 137:232-41. IF: 10.226

MANIYAR FH, **SPRENGER T**, SCHANKIN CJ, GOADSBY PJ.

Photoc hypersensitivity in the premonitory phase of migraine – A PET study.

Eur J Neurol 2014;21:1178-83. IF: 3.852

MANIYAR F, **SPRENGER T**, SCHANKIN C, GOADSBY PJ.

The origin of nausea in migraine - a PET study.

J Headache Pain 2014;15:84. IF: 3.281

MARTIN F, KANA V, MORI AC, **FISCHER D**, PARKIN N, BOLTSHAUSER E, RUSHING EJ, KLEIN A

Neurofibromatosis type 1 (NF1) with an unusually severe phenotype due to digeny for NF1 and ryanodine receptor 1 associated myopathy.

Eur J Pediatr. 2014; 173(12):1691-4. IF: 1.983

MEHLING M, EICHIN D, **HAFNER P**, HÖNGER G, **KAPPOS L**, HESS C

Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS.

Neurol Neuroimmunol Neuroinflamm. 2014;1(3):e28. IF: -

MEHLING M, TAY S.

Microfluidic cell culture.

Curr Opin Biotechnol. 2014;25:95-102. IF: 8.035

MEHLING M, FRANK T, ALBAYRAK C, TAY S

Real-time tracking, retrieval and gene expression analysis of migrating human T cells.

Lab Chip. 2014 Dec 16. [Epub ahead of print] IF: 5.748

MEIRA M, **SIEVERS C**, **HOFFMANN F**, **RASENACK M**, **KUHLE J**, **DERFUSS T**, **KAPPOS L**, **LINDBERG RL**

Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.

J Immunol Res. 2014; 2014:897249. IF: 2.934

MEIRA M, **SIEVERS C**, **HOFFMANN F**, **DERFUSS T**, **KUHLE J**, **KAPPOS L**, **LINDBERG RL**

MiR-126: a novel route for natalizumab action?

Mult Scler J 2014; 20(10):1361-70. IF: 4.863

MILLER AE, MACDONNEL R, COMI G, FREEDMAN M, **KAPPOS L**, MAEURER M, OLSSON T,

WOLINSKY J, BOZZI S, DIVE-POULETTY C, O'CONNOR P

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study Journal of Neurology

J Neurol 2014;261(9):1781-8 IF: 3.841

MILLER AE, WOLINSKY JS, **KAPPOS L**, COMI G, FREEDMAN MS, OLSSON TP, BAUER D, BENAMOR M, TRUFFINET P, O'CONNOR PW; TOPIC Study Group

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Neurol 2014;13(10):977-86. IF: 21.823

MUNGER KL, KÖCHERT K, SIMON KC, **KAPPOS L**, POLMAN CH, FREEDMAN MS, HARTUNG HP,

MILLER DH, MONTALBÁN X, EDAN G, BARKHOF F, PLEIMES D, SANDBRINK R, ASCHERIO A, POHL C

Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

Ann Clin Transl Neurol. 2014;1(8):605-17. IF: -

NAGTEGAAL GJ, POHL C, WATTJES MP, HULST HE, FREEDMAN MS, HARTUNG HP, MILLER D,

MONTALBAN X, **KAPPOS L**, EDAN G, PLEIMES D, BECKMAN K, STEMPEL B, POLMAN CH,

SANDBRINK R, BARKHOF F

Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome

Mult Scler J 2014; 20(2):234-42. IF: 4.863

O'CONNOR P, GOODMAN A, **KAPPOS L**, LUBLIN F, POLMAN C, RUDICK RA, HAUSWIRTH K,

CRISTIANO LM, FORRESTAL F, DUDA P

Long-term safety and effectiveness of natalizumab re-dosing and treatment in the STRATA MS study

Neurology 2014; 83(1): 78-86 IF: 8.303

PAPADOPOULOU A, MENEGOLA M, KUHLE J, RAMAGOPALAN SV, D'SOUZA M, SPRENGER T, RADUE EW, KAPPOS L, YALDIZLI O

Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing-remitting multiple sclerosis.

Mult Scler J 2014; 20:322-330 IF: 4.863

PAPADOPOULOU A, NAEGELIN Y, WEIER K, AMANN M, HIRSCH J, FELTEN S, YALDIZLI O, SPRENGER T, RADUE EW, KAPPOS L, GASS A.

MRI Characteristics of Periaqueductal Lesions in Multiple Sclerosis.

Mult Scler Relat Disord 2014;3:542-551. IF: 0.328

PAPADOPOULOU A, AHLHELM FJ, LYRER PA, KUHLE J.

Decision for intravenous thrombolysis in a young patient with acute vertical gaze palsy.

Acta Neurol Belg 2014 Sep 3; [Epub ahead of print] IF: 0.598

PAPADOPOULOU A, AHLHELM FJ, SPRENGER T

Intrathecal gadolinium for magnetic resonance myelography in spontaneous intracranial hypotension: valuable but may be risky--reply.

JAMA Neurol 2014;71(6):802-3. IF : 7.01

PARDINI M, UCCELLI A, GRAFMAN J, YALDIZLI O, MANCARDI G, ROCCATAGLIATA LUCA.

Isolated cognitive relapses in Multiple Sclerosis.

J Neurol Neurosurg Psychiatry 2014;85:1035-7. IF: 5.580

POLLO C, KAELIN-LANG A, OERTEL MF, STIEGLITZ L, TAUB E, FUHR P, LOZANO AM, RAABE A, SCHÜPBACH M.

Directional deep brain stimulation: an intraoperative double-blind pilot study.

Brain 2014;137(Pt 7):2015-26. IF: 10.226

PRESTEL J, VOLKERS P, MENTZER D, LEHMANN HC, HARTUNG HP, KELLER-STANILAWSKI B; GBS Study Group (including DERFUSS T).

Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany.

Pharmacoepidemiol Drug Saf. 2014; 23(11): 1192-204. IF: 3.17

PUNTES F, TOPPING J, KUHLE J, VAN DER STAR BJ, DOUIRI A, GIOVANNONI G, BAKER D, AMOR S, MALASPINA A.

Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis.

J Neurol Neurosurg Psychiatry 2014; 85:274-278 IF: 5.580

PUGIN D, FOREMAN B, DE MARCHIS GM, FERNANDEZ A, SCHMIDT JM, CZEISLER BM, MAYER SA, AGARWAL S, LESCH C, LANTIGUA H, CLAASSEN J.

Is pentobarbital safe and efficacious in the treatment of super-refractory status epilepticus: a cohort study.

Crit Care 2014; 18: R103. IF: 5.035

PUTTINI S, PANAITE PA, MERMOD N, RENAUD S, STECK AJ, KUNTZER T

Gene expression changes in chronic inflammatory demyelinating polyneuropathy skin biopsies.

J Neuroimmunol. 2014;270(1-2):61-6. IF: 2.786

RAMIEN C, PACHNIO A, SISAY S, BEGUM J, LEESE A, DISANTO G, KUHLE J, GIOVANNONI G, RICKINSON A, RAMAGOPALAN SV, MOSS P, MEIER UC.

Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort.

Mult Scler 2014; 20:751-753 IF: 4.863

RAMYEAD A, KOMETER M, STUDERUS E, KORANYI S, ITTIG S, GSCHWANDTNER U, FUHR P, RIECHER-RÖSSLER A.

Aberrant Current Source-Density and Lagged Phase Synchronization of Neural Oscillations as Markers for Emerging Psychosis.

Schizophr Bull. 2014 Sep 9. [Epub ahead of print] IF: 8.607

REDER AT, OGER JF, **KAPPOS L**, O'CONNOR P, RAMETTA M

Short-term and long-term safety and tolerability of interferon β -1b in multiple sclerosis
Mult Scler Relat Disord 2014; 3 (3): 294-302. IF: 0.328

REINHARD M, MUNZA M, VON KANNEN AL, GRIESSER-LEUTE HJ, DITTRICH R, **ENGELTER S**

Risk of recurrent cervical artery dissection during pregnancy, childbirth and puerperium.
Eur J Neurol. 2014 November 29 [Epub ahead of print] IF: 3.852

ROPELE S, KILSDONK ID, WATTJES MP, LANGKAMMER C, DE GRAAF WL, FREDERIKSEN JL, LARSSON HB, YIANNAKAS M, WHEELER-KINGSHOTT CAM, ENZINGER C, ROCCA MA, **SPRENGER T**, **AMANN M**, **KAPPOS L**, FILIPPI M, ROVIRA A, CICCARELLI O, BARKHOF F, FAZEKAS F.

Determinants of iron accumulation in deep gray matter of Multiple Sclerosis patients.
Mult Scler J 2014;20(13):1692-8. IF: 4.863

ROSTAMZADEH A, ZUMBRUNN T, JONGEN LM, NEDERKOORN PJ, MACDONALD S, **LYRER PA**,

KAPPELLE LJ, MALI WP, BROWN MM, VAN DER WORP HB, **ENGELTER S**, **BONATI LH**, on behalf of the ICSS-MRI Substudy Investigators

Predictors of acute and persisting ischemic brain lesions in patients randomized to carotid stenting or endarterectomy.

Stroke. 2014; 45(2): 591-4. IF: 6.018

SCHANKIN CJ, MANIYAR FH, **SPRENGER T**, ELLER M, GOADSBY PJ.

The relation between migraine, typical migraine aura and 'visual snow'.
Headache 2014;54:957-966. IF: 3.189

SCHEITZ JF, **SEIFFGE DJ**, TUTUNCU S, **GENSICKE H**, AUDEBERT HJ, **BONATI LH**, FIEBACH JB,

TRAENKA C, **LYRER PA**, ENDRES M, **ENGELTER S**, NOLTE CH

Dose-related effects of statins on symptomatic intracerebral hemorrhage and outcome after thrombolysis for ischemic stroke.

Stroke. 2014; 45: 509-514. IF: 6.018

SCHLAEGER R, **D'SOUZA M**, SCHINDLER C, GRIZE L, **KAPPOS L**, **FUHR P**

Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis.
Mult Scler. 2014; 20(1): 51-6. IF: 4.863

SCHLAEGER R, **D'SOUZA M**, SCHINDLER C, GRIZE L, **KAPPOS L**, **FUHR P**.

Prediction of MS disability by multimodal evoked potentials: investigation during relapse or in the relapse-free interval?

Clin Neurophysiol. 2014; 125(9): 1889-92. IF: 2.979

SCHLAEGER R, SCHINDLER C, GRIZE L, DELLAS S, RADUE EW, **KAPPOS L**, **FUHR P**.

Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years.
Mult Scler. 2014; 20(10):1348-54. IF: 4.863

SEIFFGE DJ, **TRAENKA C**, **GENSICKE H**, TSAKIRIS DA, **BONATI LH**, **PETERS N**, **LYRER P**, **ENGELTER S**

Intravenous thrombolysis in stroke patients receiving rivaroxaban.

Eur J Neurol. 2014; 21: e3-e4. IF: 3.852

SEIFFGE DJ, KARAGIANNIS A, STRBIAN D, **GENSICKE H**, **PETERS N**, **BONATI LH**, KOTISAARI K,

LEPPA M, **KEJDA-SCHARLER J**, **TRANKA C**, GINSBACH P, TATLISUMAK T, **LYRER PA**, **ENGELTER S**

Simple variables predict miserable outcome after intravenous thrombolysis.

Eur J Neurol. 2014; 21(2): 185-91. IF: 3.852

SIMPSON KN, SIMPSON AN, MAULDIN PD, HILL MD, YEATTS SD, SPILKER JA, FOSTER LD, KHATRI P, MARTIN R, JAUCH EC, KLEINDORFER D, PALESCH YY, BRODERICK JP; IMS III Investigators*. (* **ENGELTER S** Co-Investigator)

Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial.

Stroke. 2014; 45(6):1791-8. IF: 6.018

SORENSEN PS, LISBY S, GROVE R, DEROSIER F, SHACKELFORD S, HAVRDOVA E, DRULOVIC J, FILIPPI M (* **KAPPOS L** chair of the IDMC)
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study
Neurology 2014; 82(7):573-81. IF: 8.303

STRBIAN D, MICHEL P, **SEIFFGE DJ**, SAVER JL, NUMMINEN H, MERETOJA A, MURAO K, WEDER B, FORSS N, PARKKILA AK, ESKANDARI A, CORDONNIER C, DAVIS SM, **ENGELTER S**, TATLISUMAK T
Symptomatic intracranial hemorrhage after stroke thrombolysis: comparison of prediction scores.
Stroke. 2014; 45(3): 752-8. IF: 6.018

SUTTER R, MARSCH S, **FUHR P**, KAPLAN PW, **RÜEGG S**
Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study.
Neurology. 2014; 82(8): 656-64. IF 8.303

THEOFILOPOULOS S, GRIFFITHS WJ, CRICK PJ, YANG S, MELJON A, OGUNDARE M, KITAMBI SS, LOCKHART A, TUSCHL K, CLAYTON PT, MORRIS AA, MARTINEZ A, REDDY MA, MARTINUZZI A, BASSI MT, HONDA A, MIZUOCHI T, KIMURA A, NITTONO H, DE MICHELE G, CARBONE R, CRISCUOLO C, YAU JL, SECKL JR, SCHÜLE R, SCHÖLS L, SAILER AW, **KUHLE J**, FRAIDAKIS MJ, GUSTAFSSON JÅ, STEFFENSEN KR, BJÖRKHEM I, ERNFORS P, SJÖVALL J, ARENAS E, WANG Y
Cholestenic acids regulate motor neuron survival via liver X receptors.
J Clin Invest 2014; Nov 3;124:4829-4842 IF: 12.81

TOMSICK TA, YEATTS SD, LIEBESKIND DS, CARROZZELLA J, FOSTER L, GOYAL M, VON KUMMER R, HILL MD, DEMCHUK AM, JOVIN T, YAN B, ZAIDAT OO, SCHONEWILLE W, **ENGELTER S**, MARTIN R, KHATRI P, SPILKER J, PALESCH YY, BRODERICK JP; for the IMS III Investigators
Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions.
J Neurointerv Surg. 2014 [Epub ahead of print] IF: 2.495

VERMERSCH P, CZLONKOWSKA A, GRIMALDI LM, CONFAYREUX C, COMI G, **KAPPOS L**, OLSSON TP, BENAMOR M, BAUER D, TRUFFINET P, CHURCH M, MILLER AE, WOLINSKY JS, FREEDMAN MS, O'CONNOR P; TENERE TRIAL GROUP
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
Mult Scler J 2014;20(6):705-16. IF: 4.863

VIANA M, SAINAGHI PP, STECCO A, MORTARA F, **SPRENGER T**, GOADSBY PJ.
Headache in a patient with crowned dens: report of a new case.
Headache 2014;54:1211-6. IF: 3.189

WEIER K, PENNER IK, **MAGON S**, AMANN M, NAEGELIN Y, ANDELOVA M, DERFUSS T, STIPPICH C, RADUE EW, **KAPPOS L**, **SPRENGER T**
Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis.
PLoS One. 2014; 9(1): e86916 IF: 3.534

WEIER K, ESHAGHI A, **MAGON S**, RADUE EW, **KAPPOS L**, AZIMI AR, SAHRAIAN MA, **SPRENGER T**.
The role of cerebellar pathology in neuromyelitis optica – a comparison to multiple sclerosis and healthy controls.
Mult Scler J 2014 Dec 5 [Epub ahead of print] IF: 4.863

YALDIZLI O, PENNER IK, FRONTZEK K, NAEGELIN Y, AMANN M, PAPADOPOULOU A, **SPRENGER T**, **KUHLE J**, CALABRESE P, RADUE EW, **KAPPOS L**, GASS A.
The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients.
Mult Scler J 2014; 20:356-364. IF: 4.863

ZECCA C, CAPORRO M, ADAMI M, MAINETTI C, **GOBBI C**
Fumaric acid esters in psoriasis and multiple sclerosis.
Clin Exp Dermatol. 2014;39(4):488-91. IF: 1.234

ZECCA C, RICCITELLI GC, CALABRESE P, PRAVATÀ E, CANDRIAN U, GUTTMANN CR, **GOBBI C**
Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β .
BMC Neurol. 2014;14:38. IF: 2.486

ZECCA C, DIGESU GA, ROBSHAW P, PUCCINI F, KHULLAR V, TUBARO A, GOBBI C
Motor and sensory responses after percutaneous tibial nerve stimulation in multiple sclerosis patients with lower urinary tract symptoms treated in daily practice.
Eur J Neurol. 2014;21(3):506-11. IF: 3.852

ZECCA C, DIGESU GA, ROBSHAW P, SINGH A, ELNEIL S, GOBBI C
Maintenance percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in patients with multiple sclerosis: an open label, multicenter, prospective study.
J Urol. 2014;191(3):697-702. IF: 3.753

ZIMMERMANN R, GSCHWANDTNER U, BENZ N, HATZ F, SCHINDLER C, TAUB E, FUHR P.
Cognitive training in Parkinson disease: cognition-specific vs nonspecific computer training.
Neurology. 2014; 82(14):1219-26. IF: 8.303

SHANY-UR T, LIN N, ROSEN HJ, SOLLBERGER M, MILLER BL, RANKIN KP.
Self-awareness in neurodegenerative disease relies on neural structures mediating reward-driven attention.
Brain 2014;137(Pt 8):2368-81. IF: 10.226

B - BUCHBEITRÄGE, ÜBERSICHTSARBEITEN, EDITORIALS & REVIEWS

(Alphabetisch nach Erstautor sortiert)

CUTTER G, KAPPOS L
Clinical trials in multiple sclerosis
In: Goodin DS (Ed) Multiple Sclerosis and Related Disorders
Handb Clin Neurol 2014; 122:445-53.

DÉCARD BF, GSCHWANDTER U, FUHR P
Repetitive impulsassozierte Verhaltensstörungen beim idiopathischen Parkinson-Syndrom.
Schweizer Zeitschrift für Psychiatrie & Neurologie 2014; 2: 23-26

FREEDMAN M, COMI G, DE STEFANO N, BARKHOF F, POLMAN CH, UITDEHAAG BMJ, LEHR L, STUBINSKI B, KAPPOS L
Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice
Mult Scler Relat Disord 2014; 3 (2):147–55. IF: 0.328

GNANAPAVAN S, HEGEN H, KHALIL M, HEMMER B, FRANCIOTTA D, HUGHES S, HINTZEN R, JEROMIN A, HAVRDOVA E, TUMANI H, BERLOLOTTO A, COMABELLA M, FREDERIKSEN J, ALVAREZ-CERMEÑO JC, VILLAR L, GALIMBERTI D, MYHR KM, DUJMOVIC I, FAZEKAS F, IONETE C, MENGE T, KUHLE J, KEIR G, DEISENHAMMER F, TEUNISSEN C, GIOVANNONI G.
Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders.
Neurology 2014;83(13):1210-6. IF: 8.303

GRIMM A, HEILING B, AXER H
Nervultraschall bei Polyneuropathie – sinnvoll oder nicht?
Neurophysiol. Lab. 2014; 36(1): 10-22 IF: -

GRIMM A, AXER H
Hochauflösender Ultraschall in der Darstellung des Plexus brachialis und der zervikalen Nervenwurzeln.
Neurophysiol. Lab. 2014; 36(4): 135-146 IF: -

KAPPOS L, BOĀKO AN
[Oral disease modifying therapy of multiple sclerosis: the current view.].
Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(2 Vypusk 2 Rasseiannyi skleroz):63-71. IF: 0.046

KONTSCHIEDER P, DORN JF, MORRISON C, CORISH R, ZIKIC D, SELLEN A, D'SOUZA M, KAMM CP, BURGGRAFF J, TEWARIE P, VOGEL T, AZZARITO M, GLOCKER B, CHIN P, DAHLKE F, POLMAN C, KAPPOS L, UITDEHAAG B, CRIMINISI A.
Quantifying progression of multiple sclerosis via classification of depth videos.
Med Image Comput Comput Assist Interv. 2014;17(Pt 2):429-37. IF: -

LUBLIN F, REINGOLD SC, COHEN J, CUTTER G, SORENSEN P, THOMPSON A, WOLINSKY JS, BALCER L, BANWELL B, BARKHOF F, BEBO B, CALABRESI P, CLANET M, COMI G, FOX R, FREEDMAN M, GOODMAN A, INGLESE M, **KAPPOS L**, KIESEIER B, LINCOLN J, LUBETZKI C, MILLER A, MONTALBAN X, O'CONNOR P, PETKAU J, POZZILLI C, RUDICK R, SORMANI M, STUVE O, WAUBANT E, POLMAN C
Defining the clinical course of multiple sclerosis: The 2013 revisions.
Neurology 2014; 83(3): 278-286 IF: 8.303

MEHLING M, KAPPOS L (Hrsg)
Frühdiagnose und Frühintervention bei Multipler Sklerose
UNI-MED Verlag 2014; ISBN 978-3-8374-1285-7

QUAST I, **LÜNEMANN JD**
Fc Glycan-Modulated Immunoglobulin G Effector Functions
J Clin Immunol. 2014;34:S51-5. IF: 2.654

RÜEGG S
Autoimmunity and epilepsies in adults.
Epileptologie 2014; 31: 4-25. IF: -

RÜEGG S, PANZER JA
Immunotherapy for pharmaco-resistant epilepsy – ready to go? (Editorial)
Neurology 2014; 82: 1572-3. IF: 8.303

SANDOR P, GANTENBEIN A, **SPRENGER T**.
Kopfschmerzen durch Medikamentenübergebrauch: Liegt eine Suchterkrankung zugrunde?
Ars Medici 2014;16:812-813.

SEIFFGE D, TRAENKA C, HERT L, GENSICKE H, PETERS N, DE MARCHIS GM, MAYER D, VON HESSLING A, TSAKIRIS D, LYRER PA, ENGELTER S, BONATI LH
Die Neuen Antikoagulantien bei Hirnschlagpatienten: The Swiss Registry of New Anticoagulants in Stroke Patients (NOACISP): A national audit and prospective registry.
Swiss Medical Forum 2014; 14 (50): 957-959

SPRENGER T, GOADSBY PJ.
Neuroimaging in Headache Disorders.
In: Aminoff, Daroff (eds.) Encyclopedia of Neurological Sciences, 2nd edition.
Elsevier, 2014

SPRENGER T, SANDOR P.
Migränetrigger.
Ars Medici 2014;16:810-811.